These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 21531813

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Differences in multidisciplinary team assessment and treatment between patients with stage IV colon and rectal cancer.
    Segelman J, Singnomklao T, Hellborg H, Martling A.
    Colorectal Dis; 2009 Sep; 11(7):768-74. PubMed ID: 18662241
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Gene signature is associated with early stage rectal cancer recurrence.
    Kalady MF, Dejulius K, Church JM, Lavery IC, Fazio VW, Ishwaran H.
    J Am Coll Surg; 2010 Aug; 211(2):187-95. PubMed ID: 20670856
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors for survival in colorectal cancer patients.
    Laohavinij S, Maneechavakajorn J, Techatanol P.
    J Med Assoc Thai; 2010 Oct; 93(10):1156-66. PubMed ID: 20973318
    [Abstract] [Full Text] [Related]

  • 8. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer.
    Peng J, Lu JJ, Zhu J, Xu Y, Lu H, Lian P, Cai G, Cai S.
    Cancer J; 2008 Oct; 14(1):54-61. PubMed ID: 18303484
    [Abstract] [Full Text] [Related]

  • 9. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
    Fritzmann J, Morkel M, Besser D, Budczies J, Kosel F, Brembeck FH, Stein U, Fichtner I, Schlag PM, Birchmeier W.
    Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
    [Abstract] [Full Text] [Related]

  • 10. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H, Jakob C.
    J Clin Oncol; 2006 Sep 01; 24(25):4062-8. PubMed ID: 16943523
    [Abstract] [Full Text] [Related]

  • 11. CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
    Huang MY, Wang JY, Chang HJ, Kuo CW, Tok TS, Lin SR.
    Oncol Rep; 2011 May 01; 25(5):1297-306. PubMed ID: 21344162
    [Abstract] [Full Text] [Related]

  • 12. Reported symptoms, diagnostic delay and stage of colorectal cancer: a population-based study in Denmark.
    Korsgaard M, Pedersen L, Sørensen HT, Laurberg S.
    Colorectal Dis; 2006 Oct 01; 8(8):688-95. PubMed ID: 16970580
    [Abstract] [Full Text] [Related]

  • 13. Analysis of RGS2 expression and prognostic significance in stage II and III colorectal cancer.
    Jiang Z, Wang Z, Xu Y, Wang B, Huang W, Cai S.
    Biosci Rep; 2010 Dec 01; 30(6):383-90. PubMed ID: 20001967
    [Abstract] [Full Text] [Related]

  • 14. Loss of KAI1 expression in the progression of colorectal cancer.
    Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW, Barrett JC.
    Cancer Res; 1999 Nov 15; 59(22):5724-31. PubMed ID: 10582691
    [Abstract] [Full Text] [Related]

  • 15. Novel gene hBiot2 is an independent prognostic factor in colorectal cancer patients.
    Shen YM, Arbman G, Sandström P, Gullstrand P, Wei YQ, Zhang H, Rosell J, Olsson B, Peng F, Yang HS, Wang CT, Sun XF.
    Oncol Rep; 2012 Feb 15; 27(2):376-82. PubMed ID: 22024937
    [Abstract] [Full Text] [Related]

  • 16. Trends in colorectal cancer in the south of the Netherlands 1975-2007: rectal cancer survival levels with colon cancer survival.
    Lemmens V, van Steenbergen L, Janssen-Heijnen M, Martijn H, Rutten H, Coebergh JW.
    Acta Oncol; 2010 Aug 15; 49(6):784-96. PubMed ID: 20429731
    [Abstract] [Full Text] [Related]

  • 17. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
    Reimers MS, Kuppen PJ, Lee M, Lopatin M, Tezcan H, Putter H, Clark-Langone K, Liefers GJ, Shak S, van de Velde CJ.
    J Natl Cancer Inst; 2014 Nov 15; 106(11):. PubMed ID: 25261968
    [Abstract] [Full Text] [Related]

  • 18. Stage II/III cancer of the rectosigmoid junction: an independent tumor type?
    Mukai M, Kishima K, Yamazaki M, Aoki H, Izumi H, Yamamoto S, Tajima T, Tobita K, Sadahiro S, Yasuda S, Ogoshi K.
    Oncol Rep; 2011 Sep 15; 26(3):737-41. PubMed ID: 21667035
    [Abstract] [Full Text] [Related]

  • 19. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer.
    Vermeulen PB, Van den Eynden GG, Huget P, Goovaerts G, Weyler J, Lardon F, Van Marck E, Hubens G, Dirix LY.
    Br J Cancer; 1999 Jan 15; 79(2):316-22. PubMed ID: 9888475
    [Abstract] [Full Text] [Related]

  • 20. Determination of molecular marker expression can predict clinical outcome in colon carcinomas.
    Galizia G, Lieto E, Ferraraccio F, Orditura M, De Vita F, Castellano P, Imperatore V, Romano C, Ciardiello F, Agostini B, Pignatelli C.
    Clin Cancer Res; 2004 May 15; 10(10):3490-9. PubMed ID: 15161706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.